Haemonetics (HAE) Q1 Revenue Falls 4%

Medical technology firm Haemonetics (HAE) reported Q1 FY2026 GAAP revenue of $321.4 million and non-GAAP EPS of $1.10, both missing analyst estimates, with revenue declining 4.4% year-over-year primarily due to the CSL contract completion and Whole Blood line divestiture. Despite these headline misses, the company demonstrated underlying strength with non-GAAP EPS growth of 7.8% and significant margin expansion, as GAAP gross margin improved to 59.8% and operating margin to 16.8%. Management reaffirmed its full-year FY2026 guidance, projecting 6-9% organic revenue growth (excluding CSL) and adjusted EPS of $4.70-$5.00, signaling confidence in its core business trajectory and strategic focus despite near-term transitional pressures.

Analysis

Haemonetics (HAE) reported mixed results for Q1 FY2026, with headline figures missing analyst expectations while underlying operational metrics demonstrated significant strength. The company posted GAAP revenue of $321.4 million and non-GAAP EPS of $1.10, falling short of consensus estimates and marking a 4.4% year-over-year revenue decline. However, this top-line contraction is primarily attributable to the planned conclusion of a major CSL contract and the divestiture of the Whole Blood product line, masking the health of the core business. The success of the company's strategic pivot to higher-value segments is evident in its margin profile; GAAP operating margin expanded by 500 basis points to 16.8% from 11.8% in the prior-year period, contributing to a 7.8% rise in non-GAAP EPS. Organic growth in core segments was robust, with the Hospital division growing 4.2% and the Plasma division posting an impressive 29.3% organic growth excluding the CSL contract impact, driven by market share gains. A notable weak spot was a 7.2% revenue decline in Interventional Technologies due to competitive pressures. Management's reaffirmation of full-year guidance, including 6-9% organic revenue growth (ex-CSL) and adjusted EPS of $4.70-$5.00, signals strong confidence that the transitional headwinds are temporary and that performance will accelerate in the second half of the fiscal year.

Key Decisions for Investors

• Investors should look beyond the headline revenue miss, which is distorted by strategic divestitures, and focus on the significant GAAP operating margin expansion and reaffirmed full-year organic growth guidance of 6-9% as the primary indicators of the company's underlying health.
• It is critical to monitor for continued market share gains in the core Plasma and Hospital segments, while also watching for signs of stabilization in the Interventional Technologies division, which is currently a drag on overall performance.
• Given that management has guided for performance to be back-half weighted, investors should maintain a patient outlook, as the full financial benefits of the company's strategic realignment and recent contract wins may not be fully reflected until later in the fiscal year.